Nanoparticle Enrichment of Volumetrically Accurate Microsampled Blood for Enhanced Proteomic Analysis of Dried Blood

21 hours ago
1 min read

Maximizing the interpretive power and utility of proteomic data for Clinical and Precision Health research relies on several key workflow needs:

1. Discovery based workflows that yield comprehensive proteomes with high analytical precision (low assay CV’s).

2. Efficient and consistent workflows capable of handling large sample numbers. This ideally means preparative workflows that are plate-based, can be completed within 1-day, amenable to automation, robust (inter-day CV’s), and cost effective.

3. Concordance between plasma and dried blood results, where applicable. These needs apply to Plasma as well as to Dried Blood, in which an inherently more complex matrix often constrains proteome coverage and limits coverage, analytical precision, and reproducibility.

We surveyed of 4 in-house methods using plasma from patients enrolled in an in-house Alzheimer’s research study. We developed and refined a plate-based, 1-day method for both plasma and dried blood, based on the Ceres Peak platform. Finally, we preliminarily evaluated our method for utility for routine, cost effective discovery-based proteomic analysis of clinical samples.

CONCLUSIONS

In keeping with our findings and the literature, the Seer Nanoparticle enrichment platform is the gold standard for protein coverage and analytical precision. The Ceres Peak platform however represents a cost-effective complementary or alternative for plasma or VDBS proteomic analysis, and can be implemented as an optimized 2 hr plate-based single-day workflow (TEAB at 37°C). Inter-day validation confirms its robust reproducibility and strong cross-matrix correlation (Pearson r >0.86). Biological validation in ADRD samples confirms 25/31 AD-relevant biomarkers and pathway-level signal from VDBS — establishing a scalable, high-throughput platform for clinical proteomics.